AptarGroup (ATR)
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-11-05
$144.04-1.92%
Close 2026-11-05 · 1-day change
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · ATR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within materials on a research-validated quality screen. As of 2026-11-05.
The screen ranks ATR against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Materials names rated strong grew net income 63% of the time over the next year (vs 47% for the rest of the cohort, n=1960).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 7 guided quarters · 2.9% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.
Stated in 4 of 4 supplied quarters. Management reported: “Adjusting for emergency medicine destocking, Pharma delivered high single-digit core sales growth in the quarter.” “Sales in the injectables division increased 24%, mainly driven by growth in GLP-1 elastomeric components and service offerings.” Revenue was $1.019 billion in 2026-Q3.
“These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.”
“Adjusting for emergency medicine destocking, Pharma delivered high single-digit core sales growth in the quarter.”
“Consumer healthcare sales increased 4% on strong nasal decongestant and eye care solutions.”
“Sales in the injectables division increased 24%, mainly driven by growth in GLP-1 elastomeric components and service offerings.”
As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully.
Stated in 4 of 4 supplied quarters. Management reported: “These growth drivers were partially offset by the anticipated reduction in emergency medicine sales and slightly lower sales within active material science solutions.” “Consumer healthcare sales increased 3%; the division returned to growth after a period of destocking.”
“As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully.”
As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully.
Stated in 4 of 4 supplied quarters. Management reported: “Beauty’s reported sales increased 10% when compared to the prior year period, driven by a 3% benefit from currency changes and a 6% contribution from acquisitions, with core sales growth of 1%.” “Beauty’s reported sales increased 24% driven by a 7% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 10%, from a lower prior year comparison.”
In 2026, capital investments are expected to be in the range of $260 million to $280 million.
Stated in 1 of 4 supplied quarters. Management reported: “In 2026, capital investments are expected to be in the range of $260 million to $280 million.”
“In 2026, capital investments are expected to be in the range of $260 million to $280 million.”
Build the Pharma pipeline through new technologies and development programs that extend Aptar's role across the drug development cycle and therapeutic areas.
Over the trailing year it converted 1.73x of net income into operating cash flow. Historically, Materials names rated robust grew net income 56% of the time over the next year (vs 48% for the rest of the cohort, n=1429).
Most sensitive to long-term interest rates.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by executive changes. Historically, Materials names rated stable grew net income 57% of the time over the next year (vs 51% for the rest of the cohort, n=1843).
Not investment advice. As of 2026-11-05.
“These growth drivers were partially offset by the anticipated reduction in emergency medicine sales and slightly lower sales within active material science solutions.”
“Active material science solutions declined 1% due primarily to lower sales for diabetes test strips and probiotics.”
“Consumer healthcare sales increased 3%; the division returned to growth after a period of destocking.”
“As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully.”
“Beauty’s reported sales increased 10% when compared to the prior year period, driven by a 3% benefit from currency changes and a 6% contribution from acquisitions, with core sales growth of 1%.”
“Beauty’s reported sales increased 19% when compared to the prior year period, driven by a 9% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 3%.”
“Beauty’s reported sales increased 24% driven by a 7% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 10%, from a lower prior year comparison.”